- Home
- CMP vs AKBA Comparison
CMP vs AKBA Comparison
Compare CMP & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMP
- AKBA
- Stock Information
- Founded
- CMP 1993
- AKBA 2007
- Country
- CMP United States
- AKBA United States
- Employees
- CMP N/A
- AKBA N/A
- Industry
- CMP Other Metals and Minerals
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- CMP Basic Materials
- AKBA Health Care
- Exchange
- CMP Nasdaq
- AKBA Nasdaq
- Market Cap
- CMP 781.2M
- AKBA 729.1M
- IPO Year
- CMP 2003
- AKBA 2014
- Fundamental
- Price
- CMP $17.72
- AKBA $1.56
- Analyst Decision
- CMP Hold
- AKBA Strong Buy
- Analyst Count
- CMP 3
- AKBA 6
- Target Price
- CMP $20.00
- AKBA $6.25
- AVG Volume (30 Days)
- CMP 367.9K
- AKBA 6.9M
- Earning Date
- CMP 12-08-2025
- AKBA 11-10-2025
- Dividend Yield
- CMP N/A
- AKBA N/A
- EPS Growth
- CMP N/A
- AKBA N/A
- EPS
- CMP N/A
- AKBA N/A
- Revenue
- CMP $1,225,200,000.00
- AKBA $225,071,000.00
- Revenue This Year
- CMP $12.05
- AKBA $53.38
- Revenue Next Year
- CMP $4.15
- AKBA $30.53
- P/E Ratio
- CMP N/A
- AKBA N/A
- Revenue Growth
- CMP 7.27
- AKBA 32.49
- 52 Week Low
- CMP $8.60
- AKBA $1.49
- 52 Week High
- CMP $22.69
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- CMP 49.69
- AKBA 29.60
- Support Level
- CMP $16.76
- AKBA $1.64
- Resistance Level
- CMP $17.56
- AKBA $1.84
- Average True Range (ATR)
- CMP 0.66
- AKBA 0.12
- MACD
- CMP 0.05
- AKBA -0.02
- Stochastic Oscillator
- CMP 52.56
- AKBA 10.69
About CMP Compass Minerals Intl Inc
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.